More than 490 persons have been recruited for the third phase clinical trials for the Sputnik Lite vaccine against COVID-19 at the Navrongo Health Research Centre.
If successful, the vaccine will be deemed potent to protect Ghanaians against the Covid-19 virus, despite having an efficacy rate of about 70 percent.
The trials which started in June will make it possible to receive only one jab of the Sputnik Lite vaccine.
Principal Investigator for the trials, Dr. Nana Akosua Ansah told Nathaniel Nartey that the trials will be replicated in Dodowa.
Each participant is to receive 1,200 cedis as compensation. Dr. Ansah explained benefits to be derived from the clinical trials.
Meanwhile, Deputy General Secretary of the Ghana Medical Association, Dr. Titus Beyuo says the Association is aware of the Clinical trials on the Sputnik Lite vaccines and described it as a good initiative.
